2017
December 5, 2017
DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401
November 20, 2017
Mechanism of Action Studies for DNAtrix’s Oncolytic Virus DNX-2401 Presented at the 2017 Society for Neuro-Oncology Annual Meeting
November 13, 2017
DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting
May 11, 2017
DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer
April 24, 2017
Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula
2016
November 17, 2016
DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology
November 8, 2016
DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform
November 1, 2016
DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA
August 4, 2016
DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401
July 27, 2016
DNAtrix Receives European Medicines Agency PRIME Designation
February 9, 2016
DNAtrix’s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors
2015
October 1, 2015
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
June 16, 2015
DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus Expressing OX40 Ligand that Promotes Antitumor Immunity
June 8, 2015
DNAtrix Awarded Most Promising Life Science Company at 2015 Texas Life Science Forum
May 20, 2015
Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer
2014
October 14, 2014
DNAtrix Completes $20 Million Series B Financing
October 7, 2014
FDA Grants Orphan Drug Designation To DNAtrix’s Dnx-2401 For The Treatment Of Malignant Glioma
September 16, 2014
DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial
June 17, 2014
FDA Grants Fast Track Status To DNAtrix Drug DNX-2401 For Recurrent Glioblastoma
February 24, 2014
DNAtrix Awarded $10.8 Million Grant By The Cancer Prevention And Research Institute Of Texas
2013
November 18, 2013
DNAtrix Has Been Named As One Of The “Top Advanced Therapies Projects To Watch” And Will Present At The Therapeutic Area Partnerships
November 14, 2013
DNAtrix Announces Treatment Of First Patient In Study With Recurrent Glioblastoma Using DNX-2401 And Temozolomide
June 18, 2013
DNAtrix, Inc. To Present Clinical Study Results For DNX-2401 (Delta 24-Rgd), A Conditionally Replication-Competent Adenovirus
March 26, 2013
Alcyone Lifesciences And DNAtrix, Inc., To Collaborate On Unique Delivery System To Treat Brain Tumors
2012
October 23, 2012
DNAtrix And Vectorlogics Complete Merger Transaction